What is Dermatophagoides farinae (D2) specific immunoglobulin E (IgE)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Dermatophagoides farinae (D2) IgE?

Dermatophagoides farinae (D2)-specific IgE is an antibody produced by the immune system in response to allergens from the American house dust mite, Dermatophagoides farinae, and its detection in serum or skin testing identifies sensitization to this perennial indoor allergen that commonly causes allergic rhinitis, asthma, and atopic dermatitis.

Clinical Significance

Dermatophagoides farinae is one of the two most clinically important house dust mite species (along with D. pteronyssinus) that cause perennial allergic disease 1. When you measure D2-specific IgE, you are identifying patients who have developed allergic sensitization to this particular mite species.

Major Allergen Groups

The house dust mites D. farinae and D. pteronyssinus contain two major allergen groups that are immunologically cross-reactive 1:

  • Der f 1 and Der p 1 (group 1 allergens)
  • Der f 2 and Der p 2 (group 2 allergens)

More than 60% of mite-sensitive patients react to these two major allergen groups, with >70% sensitized to group 1 allergens and >80% to group 2 allergens 1, 2.

Diagnostic Testing

D2-specific IgE can be detected through:

  • Serum testing (in vitro specific IgE measurement)
  • Skin prick testing
  • Nasal lavage fluid (for local allergic rhinitis) 3

The detection of specific IgE to D. farinae should correlate with clinical history of symptoms in dusty environments or perennial symptoms 1.

Clinical Patterns

Patients sensitized to house dust mites typically present with:

  • Perennial symptoms exacerbated by dusty environments 1
  • Allergic rhinitis with less prominent ocular symptoms compared to pollen allergies 4
  • Asthma symptoms
  • Atopic dermatitis

Important Clinical Caveat

Both research and clinical experience demonstrate that allergic rhinitis can exist in rare patients with negative skin tests and/or negative in vitro tests for specific IgE 4. These patients may have local nasal IgE production and positive nasal allergen provocation tests despite negative systemic testing—a condition known as local allergic rhinitis 3.

Cross-Reactivity Considerations

Due to the high degree of cross-allergenicity between the major allergens in D. pteronyssinus and D. farinae, only 50% of the projected amounts of each species needs to be included when preparing allergen immunotherapy extracts 1. This cross-reactivity means that sensitization to one species often implies reactivity to the other.

Treatment Implications

When D2-specific IgE is detected with corresponding clinical symptoms, immunotherapy for dust mites should be considered in conjunction with avoidance measures 1. Standardized dust mite immunotherapy is more effective than crude house dust allergen extracts 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.